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1. 在缓释微球方面，通过实验优化，制备出了粒径在 2~5 μm, 外观规整圆
滑的表阿霉素缓释微球。微球 大载药率达到 4.39 %,包封率达 37.2 %，72 小
时释放了 34.9 %。进一步制备的植入型药膜也具有良好的微观结构，微球在胶
原膜内呈现规整的有序排列，缓释效果更趋明显。 
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Abstract 
Cancer is a main disease to threat the health of human being. Chemical therapy is 
an important method to treat it comparing with operation and radial therapy. 
Epirubicin is an anthracycline antibiotic and antitumor epimer of doxorubicin that has 
been used to treat a wide range of cancers. At equimolar doses epirubicin is less 
myelotoxic than doxorubicin and has a lower incidence of cardiotoxicity. Clinicly, the 
main medicament is lyophilized power and has severe side effect. To solve the 
shortcoming of clinic medicament, we develop a novel medicament of epirubicin with 
controlled release profile. 
Polylactide (PLA) has received great attention in recent years due to its good 
biocompatibility, biodegradability, and potential applications in the medical field. In 
the fields of macromolecular crystalline, polymerization for stereocontrol and 
self-assembly of amphiphilic block copolymers, crystal PLA has attracted much 
attention. However, amorphous PLA (PDLLA) is used in drug delivery system at 
large scale. 
To develop a drug delivery system of epirubicin, we prepared PDLLA 
microspheres containing epirubicin with double emulsion-solvent evaporation method. 
The sizes of the microspheres are ca. 2~5 μm, the drug loading and encapsulation 
efficiency reach ca. 4.39 % and ca. 37.2 %, respectively. Epirubicin is slow and 
pseudolinear release after an initial burst. Furthermore, we attempt to prepare collagen 
films containing epirubicin in order to reduce the burst release. 
In the field of macromolecular self-assembly, we prepared a series of 
self-assembled aggregates from polylactide in double emulsion system and 
investigated the morphologies and crystal properties of PDLLA. We observed that 
PDLLA self-assembled microarchitectures ranged from stick- to star-like aggregates, 
from sheaf-like to hexapod aggregates with the amount of glycerol increasing in the 
external aqueous phase. Moreover, the sticks and sheaves are polycrystalline. We 
further investigated the effect of various concentration of epirubicin on the 
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polycrystalline. Meanwhile, we also investigated the self-assembly of PDLLA with 
glycerol and epirubicin coexisted in emulsion. The results are similar to those PDLLA 
self-assembled microarchitectures induced by glycerol solely. 
Conclusions: we have exploited a novel medicament of epirubicin with 
controlled release profile. On the other hand, we studied the self-assembly of PDLLA 
in double emulsion system deeply and observed some interesting phenomena with 
various self-assembled microarchitectures of lactide-based polymers. We also extend 
the self-assembly of macromolecules from amphiphilic block or graft copolymers to 
general polymers, from crystal polymers to amorphous polymers. 
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第一章 绪论 











































图1-1 服用传统药物制剂后的血药浓度变化 （1，中毒极限浓度；2， 低有效
浓度） 
Figure1-1 Drug concentration changes in blood after taking the traditional doses(1, 
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放射治疗和药物治疗（化学治疗）等，但是很大程度上仍以化疗为主。各种化疗
药物，如顺铂( cisplatin )、甲氨蝶呤( methotrexate )、环磷酰胺( cyclophosphamide )、
5-氟尿嘧啶( 5-FU )、阿霉素( doxorubicin  )、表阿霉素( epirubicin )、长春新碱
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是突飞猛进。微囊化技术的进展大体分为几个阶段。20世纪80年代以前主要应用












1. 1. 3 囊材[2, 5, 19-30] 













的要求而选用A型明胶或B型明胶，用作囊材的浓度为2 % ~ 10 %。 
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可与白蛋白配合作复合材料。 
(3) 海藻酸钠：是用稀碱从褐藻中提取的多糖类化合物，能溶于各种不同温





1. 1. 3. 2 半合成高分子材料 






稳定，有表面活性，表面张力为(42 ~ 56) × 10-5  N/cm。 
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